INDIGOTINDISULFONATE SODIUM pharmaceutical API fine chemical suppliers

Subscribe to access the full database, or Start Trial
Vendor	Vendor Homepage	Vendor Sku	API Url
ChemExper Chemical Directory	⤷ Start Trial	jg PHaK^`cFdsWl@PLHOhWtL]ocs^\ddlRTtVtRbrVT`@eFmGK^kPACSTpAKD@DKH	⤷ Start Trial
Sigma-Aldrich	⤷ Start Trial	131164_SIAL	⤷ Start Trial
MP Biomedicals	⤷ Start Trial	203322	⤷ Start Trial
>Vendor	>Vendor Homepage	>Vendor Sku	>API Url

Last updated: February 19, 2026

This report analyzes the current landscape of bulk active pharmaceutical ingredient (API) sourcing for indigotindisulfonate sodium. It identifies key manufacturers, regional production concentrations, and factors influencing supply chain stability and cost. The analysis provides actionable data for procurement and R&D professionals to optimize sourcing strategies and mitigate risks.

What is Indigotindisulfonate Sodium and Its Primary Applications?

Indigotindisulfonate sodium, also known by its trade name Indigo Carmine, is a water-soluble synthetic indigo dye. Its primary pharmaceutical application is as a diagnostic dye for visualizing tissues and fluids, particularly in urological procedures. It is used to identify renal structures, assess kidney function, and detect leaks in surgical repairs. Beyond its diagnostic use, it has been explored for other niche medical applications, though these are less prevalent.

Who are the Key Manufacturers of Indigotindisulfonate Sodium Bulk API?

The production of indigotindisulfonate sodium API is concentrated among a limited number of specialized chemical manufacturers. These companies typically have expertise in organic synthesis and dye production.

Primary Manufacturers Identified:

United States Pharmacopeia (USP): While primarily a standards-setting organization, USP offers bulk API for specific research and limited commercial applications, often through approved suppliers. Their role is more in quality assurance and reference standards.
Jubilant Pharmova Limited (India): A significant player in the global API market, Jubilant has been identified as a producer of indigotindisulfonate sodium. They operate multiple manufacturing facilities in India with extensive regulatory compliance.
Maneesh Pharmaceuticals Ltd. (India): Another Indian pharmaceutical company known for its API manufacturing capabilities. Maneesh Pharmaceuticals supplies a range of pharmaceutical ingredients, including those for diagnostic agents.
AstraZeneca (formerly, through acquisitions/divestitures): Historically, larger pharmaceutical companies may have produced or sourced indigotindisulfonate sodium. However, current primary manufacturing is predominantly by specialized API producers rather than integrated drug manufacturers.
Various Chinese Chemical Manufacturers: Numerous smaller to mid-sized chemical companies in China specialize in dye synthesis and fine chemicals. Identifying specific, consistently reliable suppliers of pharmaceutical-grade indigotindisulfonate sodium requires rigorous due diligence. Companies like Nantong Acetic Acid Chemical Co., Ltd. or Zhejiang NHU Co., Ltd., while not always explicitly listing indigotindisulfonate sodium, are indicative of the type of chemical synthesis expertise present in China for related compounds. Direct sourcing from these entities necessitates thorough qualification.

Where is Bulk Indigotindisulfonate Sodium API Primarily Produced?

The geographical distribution of indigotindisulfonate sodium API production is largely dictated by centers of chemical manufacturing expertise and cost-effective production.

Key Production Regions:

India: India has emerged as a dominant global hub for API manufacturing, benefiting from a skilled workforce, established chemical infrastructure, and favorable regulatory frameworks for pharmaceutical production. Companies like Jubilant Pharmova and Maneesh Pharmaceuticals are based here.
China: China's vast chemical industry also plays a significant role. Many specialized chemical synthesis companies in China produce intermediates and finished APIs for global markets, including indigotindisulfonate sodium. However, quality control and consistent regulatory compliance can be more variable compared to established Indian manufacturers.
Europe and North America: While some niche production may exist, particularly for high-purity research-grade material or in very limited quantities, large-scale bulk API manufacturing of indigotindisulfonate sodium is less prevalent in these regions compared to Asia. This is primarily due to higher manufacturing costs. The United States Pharmacopeia (USP) plays a role in quality assurance and reference standards rather than direct bulk manufacturing.

What are the Key Factors Affecting Supply Chain Stability and Cost?

Several factors influence the availability and cost of bulk indigotindisulfonate sodium API. Understanding these dynamics is crucial for strategic procurement.

Supply Chain Stability Factors:

Regulatory Compliance: Manufacturers must adhere to stringent Good Manufacturing Practices (GMP) and pharmacopeial standards (e.g., USP, EP). Facilities undergo regular audits by regulatory bodies and customers. Non-compliance can lead to production halts and supply disruptions.
Raw Material Availability: The synthesis of indigotindisulfonate sodium relies on specific chemical precursors. Disruptions in the supply of these raw materials, whether due to geopolitical events, environmental regulations, or production issues at precursor manufacturers, can impact API availability.
Manufacturing Capacity: The number of qualified manufacturers is limited. Any unexpected increase in demand or shutdown of a key production facility can quickly strain available capacity, leading to longer lead times and price increases.
Geopolitical Risks: Reliance on specific geographic regions for production, particularly China and India, exposes the supply chain to potential disruptions from trade disputes, natural disasters, or local regulatory changes.
Quality Control and Batch Consistency: Maintaining consistent quality across batches is paramount for pharmaceutical use. Issues with purity, impurity profiles, or physical characteristics can lead to batch rejections and significant delays.

Cost Influencing Factors:

Raw Material Prices: Fluctuations in the cost of chemical precursors directly impact the manufacturing cost of indigotindisulfonate sodium.
Manufacturing Complexity and Yield: The multi-step synthesis process, along with the efficiency (yield) of each step, determines the overall production cost.
Regulatory and Quality Assurance Costs: Implementing and maintaining GMP compliance, conducting rigorous quality control testing, and obtaining necessary certifications add to the overall cost of production.
Scale of Production: Larger production volumes generally lead to lower per-unit costs due to economies of scale.
Energy and Labor Costs: These costs vary significantly by region and contribute to the final price of the API. India and China generally offer more competitive manufacturing costs in this regard.
Transportation and Logistics: Shipping costs, customs duties, and the need for specialized handling (e.g., temperature control if required) also factor into the landed cost of the API.

What are the Regulatory Requirements for Indigotindisulfonate Sodium API?

Procurement and manufacturing of indigotindisulfonate sodium API are subject to strict regulatory oversight to ensure patient safety and product efficacy.

Key Regulatory Considerations:

Pharmacopeial Standards: The API must meet the specifications outlined in relevant pharmacopeias, such as the United States Pharmacopeia (USP) or the European Pharmacopoeia (EP). These standards define purity, identification, assay, impurity limits, and other critical quality attributes.
- USP Monograph: The USP monograph for Indigotindisulfonate Sodium specifies tests for identification (UV-Vis spectrophotometry, chemical tests), assay (titration), limits for heavy metals, arsenic, chloride, sulfate, and organic impurities.
Good Manufacturing Practices (GMP): Manufacturing facilities must operate in compliance with cGMP (current Good Manufacturing Practices) as defined by regulatory bodies like the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and India's Central Drugs Standard Control Organisation (CDSCO).
Drug Master Files (DMFs): API manufacturers often file DMFs with regulatory agencies. These confidential documents detail the manufacturing process, quality controls, and facility information. Drug product manufacturers can reference these DMFs in their marketing authorization applications.
Quality Management Systems (QMS): A robust QMS is essential, encompassing change control, deviation management, CAPA (Corrective and Preventive Actions), and supplier qualification programs.
Impurity Profiling: Thorough characterization and control of process-related impurities and degradation products are critical. Any new or uncharacterized impurity above specified thresholds requires rigorous toxicological assessment.
Stability Testing: API must demonstrate adequate stability under defined storage conditions to ensure its quality throughout its shelf life.

What are the Challenges and Opportunities in Sourcing Indigotindisulfonate Sodium Bulk API?

Sourcing indigotindisulfonate sodium presents both significant challenges and potential opportunities for pharmaceutical companies.

Challenges:

Limited Supplier Pool: The relatively small number of qualified, GMP-certified manufacturers can create dependency and limit negotiation leverage.
Quality Consistency: Ensuring consistent batch-to-batch quality from diverse global suppliers requires robust supplier qualification and ongoing monitoring.
Supply Chain Vulnerability: Geopolitical instability, trade restrictions, and global health crises can disrupt the supply chain, particularly for APIs sourced from a single region.
Price Volatility: Fluctuations in raw material costs and manufacturing overheads can lead to unpredictable API pricing.
Regulatory Hurdles: Navigating the complex and evolving regulatory landscape for API sourcing across different markets requires significant expertise and resources.

Opportunities:

Supplier Diversification: Exploring and qualifying alternative suppliers in different geographic regions can enhance supply chain resilience and mitigate risks.
Strategic Partnerships: Establishing long-term partnerships with key API manufacturers can ensure preferred pricing, dedicated capacity, and proactive communication regarding potential supply issues.
Vertical Integration (Rare): For companies with significant and consistent demand, exploring limited in-house synthesis capabilities for critical intermediates or even the final API could be a long-term strategic consideration, though capital-intensive.
Advanced Analytics for Quality Control: Implementing advanced analytical techniques (e.g., LC-MS/MS, NMR) for incoming API testing can provide deeper insights into impurity profiles and ensure compliance beyond pharmacopeial minimums.
Sustainability Initiatives: Collaborating with manufacturers on sustainable production practices can align with corporate ESG (Environmental, Social, and Governance) goals and potentially lead to cost efficiencies.

Key Takeaways

The global supply of indigotindisulfonate sodium bulk API is concentrated among a select group of manufacturers, primarily in India and China. Supply chain stability is influenced by stringent regulatory compliance, raw material availability, and geopolitical factors. Cost is driven by manufacturing complexity, raw material prices, and economies of scale. Pharmaceutical companies must navigate these dynamics through robust supplier qualification, strategic diversification, and meticulous adherence to regulatory standards to ensure a reliable and cost-effective supply of this critical diagnostic agent.

Frequently Asked Questions

Can indigotindisulfonate sodium API be sourced from multiple regions simultaneously to mitigate risk? Yes, sourcing from qualified manufacturers in both India and China, or exploring any emerging suppliers in other regions, can diversify the supply base. This approach requires thorough due diligence for each potential supplier to ensure consistent GMP compliance and quality.
What is the typical lead time for ordering bulk indigotindisulfonate sodium API? Lead times can vary from 8 to 20 weeks, depending on the manufacturer's current production schedule, order volume, and existing inventory. Rush orders may incur significant premium pricing and are subject to manufacturing capacity.
Are there any active patents that could impact the generic manufacturing of indigotindisulfonate sodium API? Indigotindisulfonate sodium itself is a well-established compound, and its basic synthesis routes are largely in the public domain. Patents would more likely pertain to novel polymorphic forms, specific impurity profiles, improved synthesis methods, or unique formulations of the final drug product, rather than the API itself. A comprehensive patent landscape analysis for specific manufacturing processes or formulations would be required to confirm this.
What are the common quality control tests performed on indigotindisulfonate sodium API? Typical tests include identification (e.g., UV-Vis spectrophotometry, chemical tests), assay (e.g., titration), purity tests (e.g., HPLC for related substances), limits for heavy metals, arsenic, loss on drying, and residue on ignition, as defined by USP or EP monographs.
What is the significance of a Drug Master File (DMF) in sourcing indigotindisulfonate sodium API? A DMF, filed by the API manufacturer with regulatory authorities (like the FDA), provides confidential detailed information about the manufacturing process, facilities, and quality controls. Drug product manufacturers can reference this DMF in their applications, streamlining the regulatory review process and providing assurance of the API's quality and compliance.

Cited Sources

[1] United States Pharmacopeial Convention. (n.d.). Indigotindisulfonate Sodium. In United States Pharmacopeia and The National Formulary (USP-NF). Retrieved from USP-NF database.

[2] Jubilant Pharmova Limited. (n.d.). API Products. Retrieved from Jubilant Pharmova official website.

[3] Maneesh Pharmaceuticals Ltd. (n.d.). Active Pharmaceutical Ingredients. Retrieved from Maneesh Pharmaceuticals official website.

Bulk Pharmaceutical API Sources for INDIGOTINDISULFONATE SODIUM